Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

n about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will not be able to commence or complete one or more of the seven clinical studies noted above due to any number of factors, including lack of regulatory approval or slower than expected patient enrollment, the risk that the addition of clinical trial sites will not result in increased enrollment, and the risk that Avid may not continue to grow its manufacturing revenue, thereby increasing cashflows, due to the loss of existing clients, or in ability to acquire new clients. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed fr
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...tCall/ -- Jazz Pharmaceuticals,Inc. (Nasdaq: J...e presentation,planned for today at the Lazard Ca...e to the proximity of the release of preliminary t...nical trial of JZP-6 (sodium oxybate) for,the tre...ipates that it will release the preliminary top-li...
(Date:11/19/2008)...eneNews Limited (TSX: GEN), a company focused on d...y detection of diseases and personalized health ma...ian Colorectal Cancer Advisory Board. Drs. Lawrenc... Smith and Mr. Barry Stein will advise GeneNews on...Canadian commercialization of ColonSentry(TM), the...
(Date:11/18/2008)...(R) LLC is extremely proud to,announce the releas...system,for the Mac platform. RISLinQ(R) 4.0Mac pr...diology facilities presently using the Mac OS X pl...TLinQ, states, "The Mac OS X platform,is a world ...g system that,many radiologists and their staff h...
(Date:11/18/2008)...e/ -- Cascades Technologies, Inc. (CTi), a federal...d that it was chosen to provide a variety of web-b...earch Program. Working closely with prime contrac... (NYSE: SAI ) and the Blast Injury Research Prog...ical Research and Materiel Command (USAMRMC), CTi ...
Breaking Biology Technology:GeneNews appoints Canadian Colorectal Cancer Advisory Board 2GeneNews appoints Canadian Colorectal Cancer Advisory Board 3PETLinQ Launches RISLinQ 4.0Mac on Mac OS X Platform 2Cascades Technologies, Inc. Chosen to Deliver IT Support on a DoD Blast Injury Research Program 2Cascades Technologies, Inc. Chosen to Deliver IT Support on a DoD Blast Injury Research Program 3
...le for businesses that don,t adapt easily to an en...ate branding. , ,Local businesses such as restaura...ed and outmarketed online by larger competitors. ,...rs, physicians, and consultants struggle to adapt ...ernet. , ,Commission-driven sales organizations su...
Milwaukee Rockwell Automation Inc. has increased the quarterly dividend on its common stock to 22.5 cents per share, up from 16.5 cents, effective May 16. , ,Chairman and CEO Keith Nosbusch said t
... county businesses will receive funding for their ...ment of Commerce Technology Assistance Grant pro... will receive $11,250 to assist in its development...any will use this award to finish a patent-filing ...ff, we have not had the benefit of WARF to compl...
...nics of raising capital for your business ", when ...company should do is prepare a business plan. The ...rivate placement memorandum (PPM), the disclosure .... , ,Once the company has a good draft of the bus...(e.g., the company management, attorneys, accounta...
Other Biology Technology:Succeeding online without a Web site 2Succeeding online without a Web site 3Succeeding online without a Web site 4Due diligence and corporate clean-up 2Due diligence and corporate clean-up 3Due diligence and corporate clean-up 4
(Date:11/19/2008)...compounds created by a University of Central Flori...ast cancer tumors. , Associate Professor James T...d of breast cancer tumors in tests on mice. The c...-causing protein called STAT3, and researchers hav...he compounds are very promising," Turkson said. "T...
(Date:11/19/2008)... most reliable indicators to predict that a person...nsulin resistance. Insulin is produced in the panc...hat glucose reaches several tissues and organs in ...haracterized by the lack of tissue response to ins...f insulin by the pancreas. When the pancreas does ...
(Date:11/18/2008)...less ButtKicker(R) Kit to be Released by Amazon.co...v. 17 The Guitammer Company announ...(R) Kit for home theater, gaming and music. The ne... do-it-yourself product for home theater and gamin...urniture to become part of an affordable "4-D" the...
(Date:11/18/2008)...SWICK, N.J. Families gathering around the Thanksg...e dish that,s been given some "upscale" breeding ...age-old staple will look or taste no different tha...ing growers increase production and improve fruit ...ing them meet the increasing year-round demand for...
Breaking Biology News(10 mins):2 new compounds show promise for eliminating breast cancer tumors 2Researchers at IRB Barcelona produce more data on key genes in diabetes 2Researchers at IRB Barcelona produce more data on key genes in diabetes 3Photos: Turn Your Couch into a 'Disney' Ride for Under $300 2Photos: Turn Your Couch into a 'Disney' Ride for Under $300 3Favorite Thanksgiving dish gets 'upscale' breeding 2Part of the in group 3F A surprising new strategy helps reduce unhealthy behaviors 25712 1Part of the in group 3F A surprising new strategy helps reduce unhealthy behaviors 25712 2Operations research promises continued gains for HIV treatment in resource limited countries 25709 1Operations research promises continued gains for HIV treatment in resource limited countries 25709 2Operations research promises continued gains for HIV treatment in resource limited countries 25709 3The big gulp 3A consumers avoid extremes in soda sizes 25706 1The big gulp 3A consumers avoid extremes in soda sizes 25706 2Actuaries to Host Forum on Public Pension Disclosures 25703 1Actuaries to Host Forum on Public Pension Disclosures 25703 2Actuaries to Host Forum on Public Pension Disclosures 25703 3
... at Memorial Sloan-Kettering Cancer Center have di... stage clinical trials -- work best in patients wi...hat plays a central role in the growth and surviva...f patients with melanoma and in a minority of pati...dings, available in an advance online publication ...
...k in Current Biology, tsunami damage to coral reef...aman earthquake was occasionally spectacular, but ...o damage from chronic human misuse in the region. ...r 26, 2004, a team of ecologists from James Cook U...esia Program, and Syiah Kuala University visited a...
... would help stave off an imminent global extinctio...y in the Proceedings of the National Academy of Sc... working with the 52 member organizations of the A...tion.org ), the study identifies 794 species threa...n need of urgent conservation action at a single r...
... as containers by prehistoric peoples were likely ...ndividuals who arrived from Asia, according to a n... gourds found at archaeological sites in the Weste...rchaeological enigma by explaining how a domestica... millennia ago in places as far removed as modern-...
Other Biology News:Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs 2New study pinpoints epicenters of Earth's imminent extinctions 2Ancient humans brought bottle gourds to the Americas from Asia 2
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048
LTQ XL Linear Ion Trap from Thermo Scientific
Biology Products: